Vitale Lucas 4
4 · Orthofix Medical Inc. · Filed Mar 6, 2026
Research Summary
AI-generated summary of this filing
Orthofix (OFIX) CP&BOO Vitale Lucas Sells Shares
What Happened
- Vitale Lucas, listed as CP&BOO on the Form 4, disposed of a total of 2,312 Orthofix (OFIX) shares in two open-market sell-to-cover transactions to satisfy tax withholding related to the settlement of restricted stock units. The sales were: 1,171 shares on 2026-03-04 at a weighted average price of $12.92 for proceeds of ~$15,125, and 1,141 shares on 2026-03-05 at a weighted average price of $12.55 for proceeds of ~$14,320. Total proceeds were approximately $29,445. These were sales (routine tax-withholding), not purchases.
Key Details
- Transaction dates and prices:
- 2026-03-04: 1,171 shares sold, weighted avg price $12.92 (range reported $12.80–$13.03).
- 2026-03-05: 1,141 shares sold, weighted avg price $12.55 (range reported $12.48–$12.72).
- Total shares sold: 2,312; total proceeds ≈ $29,445.
- Purpose: Footnote (F1) states sales were made to satisfy tax withholding on RSU settlement under a pre-existing sell-to-cover requirement; no discretionary sale by the insider.
- Holdings note: Form references previously reported restricted stock units (F3: includes 138,173 previously reported RSUs) as part of the reporting person’s holdings.
- Filing timeliness: Form filed 2026-03-06; no late-filing flag noted on the provided information.
Context
- These were sell-to-cover transactions tied to RSU settlement (tax withholding), which are typically routine and do not necessarily indicate a change in insider sentiment. Retail investors often view purchases as stronger signals than routine sales for company outlook.
Insider Transaction Report
Form 4
Vitale Lucas
CP&BOO
Transactions
- Sale
Common Stock
[F1][F2][F3]2026-03-04$12.92/sh−1,171$15,125→ 165,859 total - Sale
Common Stock
[F1][F4][F3]2026-03-05$12.55/sh−1,141$14,320→ 164,718 total
Footnotes (4)
- [F1]Represents the number of shares of common stock sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units, pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). Such sale was made without the exercise of any discretion by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.80 to $13.03, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4.
- [F3]Includes 138,173 previously reported restricted stock units.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.48 to $12.72, inclusive.
Signature
/s/ J. Andres Cedron, Attorney-in-fact|2026-03-06